Drug Trial Radar · NCT06909825
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
85
Planned (sponsor's estimate)
Start
Feb 26, 2025
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Fusion Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I\&T) in combination with Olaparib in participants with mCRPC. The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 and Olaparib in participants with metastatic castration-resistant prostate cancer.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
FPI-2265Drug
PSMA ligand radiolabeled with Ac225
OlaparibDrug
Poly (ADP-ribose) polymerase (PARP) inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate anti-tumour activity of FPI-2265 administered in combination with olaparibTime frame: From first dose until approximately 12 weeks after the first administered dose of FPI-2265
- Evaluate the safety and tolerability of FPI-2265 administered in combination with olaparibTime frame: From first dose until end of long-term follow-up, 5 years from the last administered dose of FPI-2265
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Macquarie University Hospital
Macquarie Park, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Icon Cancer Centre Kurralta Park
Kurralta Park, South Australia, Australia
Peter MacCallum Cancer Center
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.